- Research works
- 114 ▲ 68% vs 2013–17
- Citations
- 1.3k 11.3 per fractional work
- Top-10% rate
- 10.3% record average 16.5%
- Open access
- 55% world 28%
Not ranked overall: Gilead Sciences (United Kingdom) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Pharmacology, Toxicology and Pharmaceutics, 6.6×. Every wedge is a field page.
- Pharmacology, Toxicology and Pharmaceutics 6.6×
- Immunology and Microbiology 6.2×
- Economics, Econometrics and Finance 3.4×
- Medicine 3.2×
- Decision Sciences 1.6×
- Veterinary 1.5×
- Health Professions 1.0×
- Biochemistry, Genetics and Molecular Biology 1.0×
- Psychology 0.7×
- Computer Science 0.7×
- Mathematics 0.5×
- Neuroscience 0.4×
- Business, Management and Accounting 0.3×
- Social Sciences 0.2×
- Nursing 0.1×
- Environmental Science 0.1×
- Physics and Astronomy 0.1×
- Agricultural and Biological Sciences 0.1×
- Engineering 0.1×
Which keywords describe research at Gilead Sciences (United Kingdom)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Lymphoma, Antiretroviral Therapy, Immune Response, Cancer Immunotherapy, Immunotherapy, CAR T Cells, Chimeric Antigen Receptor and Epidemiology.
- Preexposure Prophylaxis
- Neurotoxicity
- Intrusion Detection
- Hepatotoxicity
- Viral Load
- HIV/AIDS
- Immunogenicity
- Drug Resistance
- Biopharmaceuticals
- Monoclonal Antibodies
- Clinical Trials
- Ribavirin
- Breast Cancer
- Genetic Variation
- Metastatic Breast Cancer
- Liver Disease
- Chimeric Antigen Receptor
- Immunotherapy
- Immune Response
- Lymphoma
- Epidemiology
- Antiretroviral Therapy
- Cancer Immunotherapy
- CAR T Cells
- Antiviral Therapy
- HIV Infection
- Treatment
- Prognostic Factors
- Hepatitis C Virus
- Anomaly Detection
- Insulin Resistance
- Mortality Rates
- Cybersecurity
- Hepatocellular Carcinoma
- HIV
- Rituximab
- HIV Transmission
- Integrase Inhibitors
- Network Security
- Nucleoside Analogues
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Epidemiology5▲ 2.5×21 topics
- Lymphoma5▲ 57×2 topics
- Antiretroviral Therapy4▲ 53×5 topics
- Immune Response4▲ 14×7 topics
- Cancer Immunotherapy4▲ 51×3 topics
- Immunotherapy4▲ 11×4 topics
- CAR T Cells4▲ 97×1 topic
- Chimeric Antigen Receptor4▲ 97×1 topic
- Antiviral Therapy3▲ 57×3 topics
- Liver Disease3▲ 56×2 topics
- HIV Infection2▲ 47×2 topics
- Metastatic Breast Cancer2▲ 80×2 topics
- Treatment2▲ 3.7×7 topics
- Genetic Variation2▲ 19×3 topics
- Prognostic Factors2▲ 8.8×5 topics
- Breast Cancer2▲ 15×3 topics
- Hepatitis C Virus2▲ 102×1 topic
- Ribavirin2▲ 102×1 topic
- Anomaly Detection2▲ 11×2 topics
- Clinical Trials2▲ 4.9×6 topics
- Insulin Resistance2▲ 7.3×2 topics
- Monoclonal Antibodies2▲ 37×3 topics
- Mortality Rates2▲ 33×2 topics
- Biopharmaceuticals2▲ 56×2 topics
- Cybersecurity2▲ 12×2 topics
- Drug Resistance2▲ 11×2 topics
- Hepatocellular Carcinoma2▲ 14×3 topics
- Immunogenicity2▲ 67×2 topics
- HIV1▲ 33×3 topics
- HIV/AIDS1▲ 42×3 topics
- Rituximab1▲ 18×3 topics
- Viral Load1▲ 35×2 topics
- HIV Transmission1▲ 35×1 topic
- Hepatotoxicity1▲ 53×2 topics
- Integrase Inhibitors1▲ 121×1 topic
- Intrusion Detection1▲ 18×1 topic
- Network Security1▲ 20×1 topic
- Neurotoxicity1▲ 21×2 topics
- Nucleoside Analogues1▲ 121×1 topic
- Preexposure Prophylaxis1▲ 53×1 topic
Which research topics does Gilead Sciences (United Kingdom) publish most on?
By volume in 2022–2025: CAR-T cell therapy research, Hepatitis C virus research, HIV/AIDS drug development and treatment and Biosimilars and Bioanalytical Methods.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 CAR-T cell therapy research Oncology 4 works
- 2 Hepatitis C virus research Hepatology 2 works
- 3 HIV/AIDS drug development and treatment Infectious Diseases 1 works
- 4 Biosimilars and Bioanalytical Methods Immunology 1 works
- 5 Network Security and Intrusion Detection Computer Networks and Communications 1 works
- 6 HIV/AIDS Research and Interventions Infectious Diseases 1 works
- 7 HIV-related health complications and treatments Emergency Medicine 1 works
- 8 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 1 works
- 9 Lymphoma Diagnosis and Treatment Pathology and Forensic Medicine 1 works
- 10 Cancer Treatment and Pharmacology Oncology 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Gilead Sciences (United Kingdom)'s research output changed?
Output in 2018–2022 was 68% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Cambridge
- University of Cambridge
- Addenbrooke's Hospital
- MRC Laboratory of Molecular Biology
- Anglia Ruskin University
- AstraZeneca (United Kingdom)
- Microsoft Research (United Kingdom)
- British Antarctic Survey
- Cambridge University Hospitals NHS Foundation Trust
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.